Please select a video from the list below.
GRIPHON: Dose related efficacy with oral selexipag
Dr. Richard Channick of Mass General Hospital discussed results from the GRIPHON study of selexipag, showing improved efficacy versus placebo in preventing a morbidity or mortality event in WHO Group 1 PAH. The protocol called for dose escalation until side effects occurred and a tolerable maintenance dose was reached. Results showed that regardless of the dose achieved, an individualized approach to dosing gave equivalent efficacy, and the benefit was seen across all treatment groups regardless of PAH type or background therapy.
Recent Video
Most Viewed
Specialties :                    Search :
RESPITE Study Results
RESPITE Study Results Views - 919
ICU Management of PH
ICU Management of PH Views - 142